Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline [TheS...
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: TheStreet.com
NEW YORK and NEW ORLEANS March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://www.ksfcounsel.com/cases/nasdaqgs-rare/ Ultragenyx investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ( lewis.kahn@ksfcounsel.com ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/ to learn more. CASE DETAILS: On December 26, 2025, the Company announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteo
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud LawsuitPR Newswire
- Investors in Ultragenyx Pharmaceutical Inc. Should Contact Levi & Korsinsky Before April 6, 2026 to Discuss Your Rights – RAREGlobeNewswire
- RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RAREGlobeNewswire
- RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE MyopathyGlobeNewswire
RARE
Earnings
- 2/12/26 - Miss
RARE
Sec Filings
- 3/30/26 - Form 8-K
- 3/27/26 - Form ARS
- 3/27/26 - Form DEFA14A
- RARE's page on the SEC website